NDA 207958 – SPRITAM (levetiracetam) tablets for oral suspension: approval letter (2015)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research (to Aprecia Pharmaceuticals Company) · July 31, 2015

U.S. Food et al., 2015-07-31: FDA approval letter for Spritam (levetiracetam) tablets for oral suspension, approved 31 July 2015 as an adjunctive epilepsy treatment. The letter does not mention 3D printing; that description comes from the sponsor.

This new drug application provides for the use of SPRITAM (levetiracetam), 250 mg, 500 mg, 750 mg, and 1000 mg tablets, for oral use, in the adjunctive therapy treatment of

p.1

U.S. Food et al., 2015-07-31: FDA approval letter for Spritam (levetiracetam) tablets for oral suspension, approved 31 July 2015 as an adjunctive epilepsy treatment. The letter does not mention 3D printing; that description comes from the sponsor. Approval signed 07/31/2015 (electronic signature, William H. Dunn, Division of Neurology Products); NDA submitted 1 October 2014 under 505(b)(2); openFDA records the original submission as 'Type 3 – New Dosage Form' dated 20150731. The letter does not itself mention three-dimensional printing or ZipDose technology, so the 3D-printing characterisation comes from the sponsor, not this document. Spritam is listed as prescription with some strengths discontinued. Study type: other.